Identification of treatment goals in paediatric pulmonary arterial hypertension

European Respiratory Journal

Volumn 44, Issue 6, 2014, Pages 1616-1626

  Ploegstra, Mark Jan ^a   Douwes, Johannes M ^a   Roofthooft, Marcus T R ^a   Zijlstra, Willemijn M H ^a   Hillege, Hans L ^a   Berger, Rolf M F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN DERIVATIVE; TROPONIN T; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ECHOCARDIOGRAPHY; FUNCTIONAL STATUS; HEALTH CARE PLANNING; HEART CATHETERIZATION; HUMAN; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; NETHERLANDS; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SURVIVAL RATE; WORLD HEALTH ORGANIZATION; ADOLESCENT; BLOOD; CHILD; COHORT ANALYSIS; DISEASE COURSE; ECHOGRAPHY; FEMALE; HEART RIGHT VENTRICLE HYPERTROPHY; HYPERTENSION, PULMONARY; LUNG TRANSPLANTATION; LUNG WEDGE PRESSURE; MALE; PATIENT CARE PLANNING; PRESCHOOL CHILD; SURVIVAL; TRICUSPID VALVE REGURGITATION;

ADOLESCENT; CARDIAC CATHETERIZATION; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; ENDOTHELIN RECEPTOR ANTAGONISTS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; LUNG TRANSPLANTATION; MALE; NATRIURETIC PEPTIDE, BRAIN; PATIENT CARE PLANNING; PEPTIDE FRAGMENTS; PHOSPHODIESTERASE 5 INHIBITORS; PROSPECTIVE STUDIES; PROSTAGLANDINS I; PULMONARY WEDGE PRESSURE; SURVIVAL ANALYSIS; TRICUSPID VALVE INSUFFICIENCY;

EID: 84914151365     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00030414     Document Type: Article

References (44)

1. Berger RM, Beghetti M, Humpl T, et al. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet 2012; 379: 537-546.
2. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343-349.
3. van Loon RL, Roofthooft MT, Hillege HL, et al. Pediatric pulmonary hypertension in the Netherlands: epidemiology and characterization during the period 1991 to 2005. Circulation 2011; 124: 1755-1764.
4. Yung D, Widlitz AC, Rosenzweig EB, et al. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004; 110: 660-665.
5. van Loon RL, Roofthooft MT, Delhaas T, et al. Outcome of pediatric patients with pulmonary arterial hypertension in the era of new medical therapies. Am J Cardiol 2010; 106: 117-124.
6. Moledina S, Hislop AA, Foster H, et al. Childhood idiopathic pulmonary arterial hypertension: a national cohort study. Heart 2010; 96: 1401-1406.
7. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
8. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164-172.
9. Ivy DD, Rosenzweig EB, Lemarie JC, et al. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol 2010; 106: 1332-1338.
10. Barst RJ, McGoon MD, Elliott CG, et al. Survival in childhood pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Circulation 2012; 125: 113-122.
11. Zijlstra WM, Douwes JM, Rosenzweig EB, et al. Survival differences in pediatric pulmonary arterial hypertension: clues to a better understanding of outcome and optimal treatment strategies. J Am Coll Cardiol 2014; 63: 2159-2169.
12. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.
13. Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005; 26: 858-863.
14. Haworth SG, Beghetti M. Assessment of endpoints in the pediatric population: congenital heart disease and idiopathic pulmonary arterial hypertension. Curr Opin Pulm Med, 2010: 16, Suppl. 1, S35-S41.
15. Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Stat Med 2012; 31: 2973-2984.
16. Boissel JP, Collet JP, Moleur P, et al. Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol 1992; 43: 235-244.
17. Lammers AE, Munnery E, Hislop AA, et al. Heart rate variability predicts outcome in children with pulmonary arterial hypertension. Int J Cardiol 2010; 142: 159-165.
18. Bersohn MM, Turner MP, Traiger GL, et al. Systemic blood pressure and heart rate as prognostic indicators in pulmonary arterial hypertension. Chest 2013; 144: 959-965.
19. Henkens IR, Van Wolferen SA, Gan CT, et al. Relation of resting heart rate to prognosis in patients with idiopathic pulmonary arterial hypertension. Am J Cardiol 2009; 103: 1451-1456.
20. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102: 865-870.
21. Bernus A, Wagner BD, Accurso F, et al. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest 2009; 135: 745-751.
22. Takatsuki S, Wagner BD, Ivy DD. B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension. Congenit Heart Dis 2012; 7: 259-267.
23. Van Albada ME, Loot FG, Fokkema R, et al. Biological serum markers in the management of pediatric pulmonary arterial hypertension. Pediatr Res 2008; 63: 321-327.
24. Lammers AE, Hislop AA, Haworth SG. Prognostic value of B-type natriuretic peptide in children with pulmonary hypertension. Int J Cardiol 2009; 135: 21-26.
25. Torbicki A, Kurzyna M, Kuca P, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 2003; 108: 844-848.
26. Nagaya N, Uematsu M, Satoh T, et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 1999; 160: 487-492.
27. Douwes JM, Roofthooft MT, Bartelds B, et al. Pulsatile haemodynamic parameters are predictors of survival in paediatric pulmonary arterial hypertension. Int J Cardiol 2013; 168: 1370-1377.
28. Raymond RJ, Hinderliter AL, Willis PW, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002; 39: 1214-1219.
29. Alkon J, Humpl T, Manlhiot C, et al. Usefulness of the right ventricular systolic to diastolic duration ratio to predict functional capacity and survival in children with pulmonary arterial hypertension. Am J Cardiol 2010; 106: 430-436.
30. van Wolferen SA, Marcus JT, Boonstra A, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007; 28: 1250-1257.
31. Moledina S, Pandya B, Bartsota M, et al. Prognostic significance of cardiac magnetic resonance imaging in children with pulmonary hypertension. Circ Cardiovasc Imaging 2013; 6: 407-414.
32. Jone PN, Hinzman J, Wagner BD, et al. Right ventricular to left ventricular diameter ratio at end-systole in evaluating outcomes in children with pulmonary hypertension. J Am Soc Echocardiogr 2014; 27: 172-178.
33. Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2012; 39: 589-596.
34. Barst RJ, Chung L, Zamanian RT, et al. Functional class improvement and three-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL registry. Chest 2013; 144: 160-168.
35. Beghetti M, Berger RM, Schulze-Neick I, et al. Diagnostic evaluation of paediatric pulmonary hypertension in current clinical practice. Eur Respir J 2013; 42: 689-700.
36. McQuillan BM, Picard MH, Leavitt M, et al. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. Circulation 2001; 104: 2797-2802.
37. Li AM, Yin J, Au JT, et al. Standard reference for the six-minute-walk test in healthy children aged 7 to 16 years. Am J Respir Crit Care Med 2007; 176: 174-180.
38. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000; 56: 337-344.
39. Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998; 31: 202-208.
40. Koestenberger M, Ravekes W, Everett AD, et al. Right ventricular function in infants, children and adolescents: reference values of the tricuspid annular plane systolic excursion (TAPSE) in 640 healthy patients and calculation of z score values. J Am Soc Echocardiogr 2009; 22: 715-719.
41. Ciarka A, Doan V, Velez-Roa S, et al. Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 181: 1269-1275.
42. Galie N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 394-403.
43. Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012; 60: 1192-1201.
44. Mathai SC, Puhan MA, Lam D, et al. The minimal important difference in the 6-minute walk test for patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2012; 186: 428-433.